Page last updated: 2024-10-18

dihydroxyphenylalanine and Cancer of Pancreas

dihydroxyphenylalanine has been researched along with Cancer of Pancreas in 27 studies

Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.

Research Excerpts

ExcerptRelevanceReference
"(18)F-fluorodihydroxyphenylalanine (FDOPA) is a powerful tool for the diagnosis and detection of neuroendocrine tumors when planning and monitoring surgical and oncologic therapies."8.9018F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. ( Forsback, S; Kauhanen, S; Kemppainen, J; Minn, H; Seppänen, M, 2014)
"In recent years, 6-l-18F-fluorodihydroxyphenylalanine (18F-DOPA) PET has emerged as a new diagnostic tool for the imaging of neuroendocrine tumors."8.846-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. ( Brouwers, AH; Chirakal, R; Gulenchyn, KY; Jager, PL; Koopmans, KP; Marriott, CJ, 2008)
"(18)F-fluorodihydroxyphenylalanine (FDOPA) PET seems to be of limited value to localize pancreatic insulin-secreting tumors in adult with hyperinsulinemic hypoglycemia."7.81Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia. ( Bachellier, P; Bahougne, T; Goichot, B; Imperiale, A; Namer, IJ; Taïeb, D, 2015)
"(18)F-fluorodihydroxyphenylalanine (FDOPA) is a powerful tool for the diagnosis and detection of neuroendocrine tumors when planning and monitoring surgical and oncologic therapies."4.9018F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. ( Forsback, S; Kauhanen, S; Kemppainen, J; Minn, H; Seppänen, M, 2014)
"In recent years, 6-l-18F-fluorodihydroxyphenylalanine (18F-DOPA) PET has emerged as a new diagnostic tool for the imaging of neuroendocrine tumors."4.846-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. ( Brouwers, AH; Chirakal, R; Gulenchyn, KY; Jager, PL; Koopmans, KP; Marriott, CJ, 2008)
"(18)F-fluorodihydroxyphenylalanine (FDOPA) PET seems to be of limited value to localize pancreatic insulin-secreting tumors in adult with hyperinsulinemic hypoglycemia."3.81Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia. ( Bachellier, P; Bahougne, T; Goichot, B; Imperiale, A; Namer, IJ; Taïeb, D, 2015)
" 6-L-¹⁸F-fluorodihydroxyphenylalanine (¹⁸F-FDOPA) positron emission tomography (PET) is a relatively new metabolic imaging tracer proposed for the use of localizing sites of neuroendocrine tumors."3.78Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome. ( Gesuwan, K; Herscovitch, P; Kebebew, E; Kitano, M; Linehan, WM; Millo, C; Nilubol, N; Weisbrod, AB, 2012)
"In cancer patients with hypersplenism-related thrombocytopenia, PSAE is a safe intervention that effects a durable elevation in platelet counts across a range of malignancies and following the re-initiation of chemotherapy."2.73 ( Aasbrenn, M; Abd El-Aty, AM; Abdu, A; Abraha, HB; Achour, A; Acquaroni, M; Addeo, P; Agback, P; Agback, T; Al-Alwan, M; Al-Mazrou, A; Al-Mohanna, F; Aliste, M; Almquist, J; Andel, J; Ando, M; Angelov, A; Annuar, MSM; Antwi, K; Arroliga, AC; Arruda, SLM; Asch, SM; Averous, G; Ayaz, S; Ayer, GB; Bachellier, P; Ball, S; Banijamali, AR; Barden, TC; Bartoncini, S; Bedanie, G; Bellò, M; Benić, F; Berhe, GG; Bertiger, G; Beumer, JH; Bhandari, B; Bond, DS; Boules, M; Braüner Christensen, J; Brown-Johnson, C; Burgstaller, S; Cao, L; Capasso, C; Carlevato, R; Carvalho, AE; Ceci, F; Chagas, ATA; Chavan, SG; Chen, AP; Chen, HC; Chen, J; Chen, Q; Chen, Y; Chen, YF; Christ, ER; Chu, CW; Covey, JM; Coyne, GO'; Cristea, MC; Currie, MG; Dahdal, DN; Dai, L; Dang, Z; de Abreu, NL; de Carvalho, KMB; de la Plaza Llamas, R; Deandreis, D; Del Prete, S; Dennis, JA; Deur, J; Díaz Candelas, DA; Divyapriya, G; Djanani, A; Dodig, D; Doki, Y; Doroshow, JH; Dos Santos, RC; Durairaj, N; Dutra, ES; Eguchi, H; Eisterer, W; Ekmann, A; Elakkad, A; Evans, WE; Fan, W; Fang, Z; Faria, HP; Farris, SG; Fenoll, J; Fernandez-Botran, R; Flores, P; Fujita, J; Gan, L; Gandara, DR; Gao, X; Garcia, AA; Garrido, I; Gebru, HA; Gerger, A; Germano, P; Ghamande, S; Ghebeh, H; Giver Jensen, T; Go, A; Goichot, B; Goldwater, M; Gontero, P; Greil, R; Gruenberger, B; Guarneri, A; Guo, Y; Gupta, S; Haxholdt Lunn, T; Hayek, AJ; He, ML; Hellín, P; Hepprich, M; Hernández de Rodas, E; Hill, A; Hndeya, AG; Holdsworth, LM; Hookey, L; Howie, W; Hu, G; Huang, JD; Huang, SY; Hubmann, E; Hwang, SY; Imamura, H; Imperiale, A; Jiang, JQ; Jimenez, JL; Jin, F; Jin, H; Johnson, KL; Joseph, A; Juwara, L; Kalapothakis, E; Karami, H; Karayağiz Muslu, G; Kawabata, R; Kerwin, J; Khan, I; Khin, S; Kidanemariam, HG; Kinders, RJ; Klepov, VV; Koehler, S; Korger, M; Kovačić, S; Koyappayil, A; Kroll, MH; Kuban, J; Kummar, S; Kung, HF; Kurokawa, Y; Laengle, F; Lan, J; Leal, HG; Lee, MH; Lemos, KGE; Li, B; Li, G; Li, H; Li, X; Li, Y; Li, Z; Liebl, W; Lillaz, B; Lin, F; Lin, L; Lin, MCM; Lin, Y; Lin, YP; Lipton, RB; Liu, J; Liu, W; Liu, Z; Lu, J; Lu, LY; Lu, YJ; Ludwig, S; Luo, Y; Ma, L; Ma, W; Machado-Coelho, GLL; Mahmoodi, B; Mahoney, M; Mahvash, A; Mansour, FA; Mao, X; Marinho, CC; Masferrer, JL; Matana Kaštelan, Z; Melendez-Araújo, MS; Méndez-Chacón, E; Miletić, D; Miller, B; Miller, E; Miller, SB; Mo, L; Moazzen, M; Mohammadniaei, M; Montaz-Rosset, MS; Mousavi Khaneghah, A; Mühlethaler, K; Mukhopadhyay, S; Mulugeta, A; Nambi, IM; Navarro, S; Nazmara, S; Neumann, HJ; Newman, EM; Nguyen, HTT; Nicolato, AJPG; Nicolotti, DG; Nieva, JJ; Nilvebrant, J; Nocentini, A; Nugent, K; Nunez-Rodriguez, DL; Nygren, PÅ; Oberli, A; Oderda, M; Odisio, B; Oehler, L; Otludil, B; Overman, M; Özdemir, M; Pace, KA; Palm, H; Parchment, RE; Parise, R; Passera, R; Pavlovic, J; Pecherstorfer, M; Peng, Z; Pérez Coll, C; Petzer, A; Philipp-Abbrederis, K; Pichler, P; Piekarz, RL; Pilati, E; Pimentel, JDSM; Posch, F; Prager, G; Pressel, E; Profy, AT; Qi, P; Qi, Y; Qiu, C; Rajasekhar, B; Ramia, JM; Raynor, HA; Reis, VW; Reubi, JC; Ricardi, U; Riedl, JM; Romano, F; Rong, X; Rubinstein, L; Rumboldt, Z; Sabir, S; Safaeinili, N; Sala, BM; Sandoval Castillo, L; Sau, M; Sbhatu, DB; Schulte, T; Scott, V; Shan, H; Shao, Y; Shariatifar, N; Shaw, JG; She, Y; Shen, B; Shernyukov, A; Sheth, RA; Shi, B; Shi, R; Shum, KT; Silva, JC; Singh, A; Sinha, N; Sirajudeen, AAO; Slaven, J; Sliwa, T; Somme, F; Song, S; Steinberg, SM; Subramaniam, R; Suetta, C; Sui, Y; Sun, B; Sun, C; Sun, H; Sun, Y; Supuran, CT; Surger, M; Svartz, G; Takahashi, T; Takeno, A; Tam, AL; Tang, Z; Tanner, JA; Tannich, E; Taye, MG; Tekle, HT; Thomas, GJ; Tian, Y; Tobin, JV; Todd Milne, G; Tong, X; Une, C; Vela, N; Venkateshwaran, U; Villagrán de Tercero, CI; Wakefield, JD; Wampfler, R; Wan, M; Wang, C; Wang, J; Wang, L; Wang, S; Waser, B; Watt, RM; Wei, B; Wei, L; Weldemichael, MY; Wellmann, IA; Wen, A; Wild, D; Wilthoner, K; Winder, T; Wing, RR; Winget, M; Wöll, E; Wong, KL; Wong, KT; Wu, D; Wu, Q; Wu, Y; Xiang, T; Xiang, Z; Xu, F; Xu, L; Yamasaki, M; Yamashita, K; Yan, H; Yan, Y; Yang, C; Yang, H; Yang, J; Yang, N; Yang, Y; Yau, P; Yu, M; Yuan, Q; Zhan, S; Zhang, B; Zhang, H; Zhang, J; Zhang, N; Zhang, Y; Zhao, X; Zheng, BJ; Zheng, H; Zheng, W; Zhou, H; Zhou, X; Zhu, S; Zimmer, DP; Zionts, D; Zitella, A; Zlott, J; Zolfaghari, K; Zuo, D; Zur Loye, HC; Žuža, I, 2007)
"In all carcinoid patients (18)F-DOPA PET and (11)C-5-HTP PET detected more lesions than SRS (P < ."1.35Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. ( Brouwers, AH; de Vries, EG; Elsinga, PH; Jager, PL; Kema, IP; Koopmans, KP; Neels, OC; Sluiter, WJ; Vanghillewe, K, 2008)

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-19902 (7.41)18.7374
1990's0 (0.00)18.2507
2000's9 (33.33)29.6817
2010's13 (48.15)24.3611
2020's3 (11.11)2.80

Authors

AuthorsStudies
Mitrofanova, LB1
Perminova, AA1
Ryzhkova, DV1
Sukhotskaya, AA1
Bairov, VG1
Nikitina, IL1
Jullien, M1
Reichert, T1
D'Anella, P1
Castinetti, F2
Barlier, A1
Brue, T1
Taieb, D5
Cuny, T1
Yang, N1
Tanner, JA1
Zheng, BJ1
Watt, RM1
He, ML1
Lu, LY1
Jiang, JQ1
Shum, KT1
Lin, YP1
Wong, KL1
Lin, MCM1
Kung, HF1
Sun, H1
Huang, JD1
Marinho, CC1
Nicolato, AJPG1
Reis, VW1
Dos Santos, RC1
Silva, JC1
Faria, HP1
Machado-Coelho, GLL1
Sun, Y2
Zhang, N1
Wang, J2
Guo, Y1
Sun, B1
Liu, W1
Zhou, H1
Yang, C1
Wei, L1
Ball, S1
Dennis, JA1
Bedanie, G1
Nugent, K1
Hayek, AJ1
Scott, V1
Yau, P1
Zolfaghari, K1
Goldwater, M1
Almquist, J1
Arroliga, AC1
Ghamande, S1
Wu, Q1
Ma, W1
Shi, R1
Zhang, B1
Mao, X1
Zheng, W1
Sbhatu, DB1
Berhe, GG1
Hndeya, AG1
Abraha, HB1
Abdu, A1
Gebru, HA1
Taye, MG1
Mulugeta, A1
Weldemichael, MY1
Tekle, HT1
Kidanemariam, HG1
Surger, M1
Angelov, A1
Liebl, W1
Hookey, L1
Bertiger, G1
Johnson, KL1
Boules, M1
Ando, M1
Dahdal, DN1
Riedl, JM1
Posch, F1
Prager, G1
Eisterer, W1
Oehler, L1
Sliwa, T1
Wilthoner, K1
Petzer, A1
Pichler, P1
Hubmann, E1
Winder, T1
Burgstaller, S1
Korger, M1
Andel, J1
Greil, R1
Neumann, HJ1
Pecherstorfer, M1
Philipp-Abbrederis, K1
Djanani, A1
Gruenberger, B1
Laengle, F1
Wöll, E1
Gerger, A1
Evans, WE1
Raynor, HA1
Howie, W1
Lipton, RB1
Thomas, GJ1
Wing, RR1
Pavlovic, J1
Farris, SG1
Bond, DS1
Hepprich, M1
Antwi, K1
Waser, B1
Reubi, JC1
Wild, D1
Christ, ER1
Braüner Christensen, J1
Aasbrenn, M1
Sandoval Castillo, L1
Ekmann, A1
Giver Jensen, T1
Pressel, E1
Haxholdt Lunn, T1
Suetta, C1
Palm, H1
Mansour, FA1
Al-Mazrou, A1
Al-Mohanna, F1
Al-Alwan, M1
Ghebeh, H1
Brown-Johnson, C1
Safaeinili, N1
Zionts, D1
Holdsworth, LM1
Shaw, JG1
Asch, SM1
Mahoney, M1
Winget, M1
Luo, Y1
Shan, H1
Gao, X1
Qi, P1
Li, Y2
Li, B1
Rong, X1
Shen, B1
Zhang, H1
Lin, F1
Tang, Z1
Fang, Z1
Peng, Z1
Jimenez, JL1
Ayer, GB1
Klepov, VV1
Pace, KA1
Zur Loye, HC1
Acquaroni, M1
Svartz, G1
Pérez Coll, C1
Otludil, B1
Ayaz, S1
Hill, A1
Elakkad, A1
Kuban, J1
Sabir, S1
Odisio, B1
Huang, SY1
Mahvash, A1
Miller, E1
Kroll, MH1
Overman, M1
Tam, AL1
Gupta, S1
Sheth, RA1
Deandreis, D1
Guarneri, A1
Ceci, F1
Lillaz, B1
Bartoncini, S1
Oderda, M1
Nicolotti, DG1
Pilati, E1
Passera, R1
Zitella, A1
Bellò, M1
Parise, R1
Carlevato, R1
Ricardi, U1
Gontero, P1
Coyne, GO'1
Wang, L2
Zlott, J1
Juwara, L1
Covey, JM1
Beumer, JH1
Cristea, MC1
Newman, EM1
Koehler, S1
Nieva, JJ1
Garcia, AA1
Gandara, DR1
Miller, B1
Khin, S1
Miller, SB1
Steinberg, SM1
Rubinstein, L1
Parchment, RE1
Kinders, RJ1
Piekarz, RL1
Kummar, S1
Chen, AP1
Doroshow, JH1
Li, X2
Chen, J2
Gan, L1
Tian, Y1
Shi, B1
Yang, Y1
Li, G1
Wu, D1
Wen, A1
Wu, Y1
Zhou, X1
Koyappayil, A1
Chavan, SG1
Mohammadniaei, M1
Go, A1
Hwang, SY1
Lee, MH1
Kurokawa, Y1
Yamashita, K1
Kawabata, R1
Fujita, J1
Imamura, H1
Takeno, A1
Takahashi, T1
Yamasaki, M1
Eguchi, H1
Doki, Y1
Schulte, T1
Sala, BM1
Nilvebrant, J1
Nygren, PÅ1
Achour, A1
Shernyukov, A1
Agback, T1
Agback, P1
Karami, H1
Shariatifar, N1
Nazmara, S1
Moazzen, M1
Mahmoodi, B1
Mousavi Khaneghah, A1
Sinha, N1
Mukhopadhyay, S1
Sau, M1
Qi, Y1
Wan, M1
Abd El-Aty, AM1
Li, H2
Cao, L1
She, Y1
Shao, Y1
Jin, F1
Wang, S1
Melendez-Araújo, MS1
Lemos, KGE1
Arruda, SLM1
Dutra, ES1
de Carvalho, KMB1
de la Plaza Llamas, R1
Díaz Candelas, DA1
Ramia, JM1
Zhu, S1
Liu, Z1
Lu, J2
Xiang, Z1
Lan, J1
Liu, J1
Yu, M1
Chen, Y2
Sirajudeen, AAO1
Annuar, MSM1
Subramaniam, R1
Somme, F1
Montaz-Rosset, MS1
Averous, G2
Deur, J1
Goichot, B2
Bachellier, P4
Addeo, P2
Imperiale, A5
Xu, L1
Li, Z2
Song, S1
Chen, Q1
Mo, L1
Wang, C1
Fan, W1
Yan, Y1
Tong, X1
Yan, H1
Singh, A1
Chen, HC1
Chen, YF1
Lu, YJ1
Wong, KT1
Chu, CW1
Banijamali, AR1
Carvalho, AE1
Wakefield, JD1
Germano, P1
Barden, TC1
Tobin, JV1
Zimmer, DP1
Masferrer, JL1
Profy, AT1
Currie, MG1
Todd Milne, G1
Zhang, Y1
Yang, H1
Dang, Z1
Zhan, S1
Sun, C1
Hu, G1
Lin, Y1
Yuan, Q1
Karayağiz Muslu, G1
Özdemir, M1
Del Prete, S1
Nocentini, A1
Supuran, CT1
Capasso, C1
Chagas, ATA1
Ludwig, S1
Pimentel, JDSM1
de Abreu, NL1
Nunez-Rodriguez, DL1
Leal, HG1
Kalapothakis, E1
Zhang, J1
Lin, L1
Dodig, D1
Kovačić, S1
Matana Kaštelan, Z1
Žuža, I1
Benić, F1
Slaven, J1
Miletić, D1
Rumboldt, Z1
Fernandez-Botran, R1
Wellmann, IA1
Une, C1
Méndez-Chacón, E1
Hernández de Rodas, E1
Bhandari, B1
Villagrán de Tercero, CI1
Nguyen, HTT1
Romano, F1
Wampfler, R1
Mühlethaler, K1
Tannich, E1
Oberli, A1
Yang, J1
Xiang, T1
Dai, L1
Zhao, X1
Ma, L1
Zuo, D1
Wei, B1
Sui, Y1
Xu, F1
Zheng, H1
Qiu, C1
Jin, H1
Kerwin, J1
Khan, I1
Rajasekhar, B1
Venkateshwaran, U1
Durairaj, N1
Divyapriya, G1
Nambi, IM1
Joseph, A1
Aliste, M1
Garrido, I1
Flores, P1
Hellín, P1
Vela, N1
Navarro, S1
Fenoll, J1
Ansquer, C1
Touchefeu, Y1
Faivre-Chauvet, A1
Leux, C1
Le Bras, M1
Régenet, N1
Fleury, V1
Maucherat, B1
Senellart, H1
Guyetant, S1
Carlier, T1
Scotet-Cérato, E1
Rauscher, A1
Frampas, E1
Kraeber-Bodéré, F1
Berends, AMA1
Kerstens, MN1
Bolt, JW1
Links, TP1
Korpershoek, E1
de Krijger, RR1
Walenkamp, AME1
Noordzij, W1
van Etten, B1
Kats-Ugurlu, G1
Brouwers, AH3
van der Horst-Schrivers, ANA1
Cuccurullo, V1
Di Stasio, GD1
Mansi, L1
Sood, A1
Basher, RK1
Kang, M1
Shukla, J1
Behera, A1
Walia, R1
Nada, R1
Mittal, BR1
Bhattacharya, A1
Namer, IJ4
Legmann, P1
Prat, F1
Chevallier, P1
Tenenbaum, F1
Minn, H2
Kemppainen, J1
Kauhanen, S3
Forsback, S1
Seppänen, M3
Sebag, F2
Vix, M1
Kessler, L2
Moreau, F1
Guillet, B1
Mundler, O2
Bahougne, T1
Shamim, SA1
Kumar, A1
Kumar, R1
Detour, J1
Pierre, A1
Boisson, F1
Kreutter, G1
Lavaux, T1
Brasse, D1
Marchand, P1
Nuutila, P2
Tessonnier, L1
Ghander, C1
De Micco, C1
Reynaud, R1
Palazzo, FF1
Conte-Devolx, B1
Henry, JF1
Buck, AK1
Herrmann, K1
Eckel, F1
Beer, AJ1
Weisbrod, AB1
Kitano, M1
Gesuwan, K1
Millo, C1
Herscovitch, P1
Nilubol, N1
Linehan, WM1
Kebebew, E1
Jager, PL3
Koopmans, KP3
de Vries, EG2
Gullichsen, R1
Salonen, A1
Alanen, K1
Parkkola, R1
Solin, O1
Bergman, J1
Sane, T1
Salmi, J1
Välimäki, M1
Hardy, OT1
Hernandez-Pampaloni, M1
Saffer, JR1
Scheuermann, JS1
Ernst, LM1
Freifelder, R1
Zhuang, H1
MacMullen, C1
Becker, S1
Adzick, NS1
Divgi, C1
Alavi, A1
Stanley, CA1
Kapoor, RR1
Gilbert, C1
Mohnike, K1
Blankenstein, O1
Fuechtner, F1
Hussain, K1
Chirakal, R1
Marriott, CJ1
Gulenchyn, KY1
Neels, OC1
Kema, IP1
Elsinga, PH1
Sluiter, WJ1
Vanghillewe, K1
Ambrosini, V1
Tomassetti, P1
Castellucci, P1
Campana, D1
Montini, G1
Rubello, D1
Nanni, C1
Rizzello, A1
Franchi, R1
Fanti, S1
Käser, H1
Wagner, HP1
Zuppinger, K1
Zurbrügg, R1
Delacretaz, J1
Emch, M1
Schellhorn, JP1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Localization of Focal Forms of Hyperinsulinism of Infancy With 18F-labeled L-fluoro-DOPA PET Scan[NCT00674440]Phase 2106 participants (Actual)Interventional2004-12-31Completed
The Use of Fluorodopa F 18 Positron Emission Tomography Combined With Computed Tomography in Congenital Hyperinsulinism and Insulinoma[NCT02021604]Phase 1250 participants (Anticipated)Interventional2013-10-09Recruiting
A Phase II Safety and Efficacy Study of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Children With Hyperinsulinemic Hypoglycemia[NCT01468454]Phase 2130 participants (Actual)Interventional2009-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Safety of F-DOPA PET

Number of Participants with Adverse Events (NCT00674440)
Timeframe: 72 hours maximum or prior to pancreatic surgery

InterventionParticipants (Count of Participants)
All Subjects Who Had PET0

The Accuracy of FDOPA PET to Identify Focal Forms of Hyperinsulinism

Comparison of PET scan results with outcome of surgery and histopathology results confirmed as focal or diffuse (NCT00674440)
Timeframe: up to 1 month post surgical intervention

InterventionParticipants (Count of Participants)
True Negatives (PET diffuse/surgery diffuse)False negatives (PET diffuse/surgery focal):False positives (PET focal/surgery diffuse):True positives (PET focal/surgery focal):
Subjects Who Had PET and Surgery406346

Safety of 18F-DOPA PET/CT Scan - Number of Participants With Adverse Events

"To further evaluate the safety of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET/CT imaging in infants and children with congenital hyperinsulinism~- subjects are monitored clinically for any signs or symptoms of adverse events for 72 hours post PET. Adverse events are documented and followed to resolution" (NCT01468454)
Timeframe: evaluated with 72 hours or prior to pancreatic surgery (if any)

InterventionParticipants (Count of Participants)
(18F-DOPA) PET/CT Imaging0

Accuracy of 18F-DOPA PET/CT Scans to Detect Focal Lesions in Children With Congenital Hyperinsulinism

To determine the sensitivity and specificity of 18F-DOPA PET/CT for the detection of a focal pancreatic lesion in infants and children with poorly controlled hyperinsulinemic hypoglycemia. (NCT01468454)
Timeframe: Surgery typically occured within a week post PET

Interventioncases (Number)
True Negatives (PET diffuse/surgery diffuse)False negatives (PET diffuse/surgery focal):False positives (PET focal/surgery diffuse):True positives (PET focal/surgery focal):
PET/CT Imaging vs Surgical Result3410452

Reviews

4 reviews available for dihydroxyphenylalanine and Cancer of Pancreas

ArticleYear
Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours.
    Current radiopharmaceuticals, 2019, Volume: 12, Issue:2

    Topics: Animals; Dihydroxyphenylalanine; Dimerization; Edetic Acid; Fluorodeoxyglucose F18; Glucagon-Like Pe

2019
18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
    PET clinics, 2014, Volume: 9, Issue:1

    Topics: Adrenal Gland Neoplasms; Carcinoma, Neuroendocrine; Dihydroxyphenylalanine; Humans; Intestinal Neopl

2014
PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
    PET clinics, 2015, Volume: 10, Issue:3

    Topics: Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Gast

2015
6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008, Volume: 49, Issue:4

    Topics: Adenoma, Islet Cell; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Neuroendocrine Tumors; Pancrea

2008

Trials

1 trial available for dihydroxyphenylalanine and Cancer of Pancreas

ArticleYear
    Angewandte Chemie (Weinheim an der Bergstrasse, Germany), 2007, Aug-27, Volume: 119, Issue:34

    Topics: 3-Hydroxybutyric Acid; Acetazolamide; Acrylates; Administration, Intravenous; Adolescent; Adult; Aer

2007

Other Studies

22 other studies available for dihydroxyphenylalanine and Cancer of Pancreas

ArticleYear
Differential Morphological Diagnosis of Various Forms of Congenital Hyperinsulinism in Children.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Adenoma; Adenoma, Islet Cell; Congenital Hyperinsulinism; Diagnosis, Differential; Dihydroxyphenylal

2021
Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.
    Annales d'endocrinologie, 2020, Volume: 81, Issue:1

    Topics: Dihydroxyphenylalanine; Female; Humans; Middle Aged; Multiple Endocrine Neoplasia Type 1; Neuroendoc

2020
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
    Clinical nuclear medicine, 2021, Mar-01, Volume: 46, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Humans; Intestinal Neoplasms; Male;

2021
False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
    European journal of endocrinology, 2018, Volume: 179, Issue:2

    Topics: Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; False Positive Reactions; Female; Huma

2018
68Ga-DOTA-Exendin PET-MRI Fusion Imaging in a Case of Insulinoma.
    Clinical nuclear medicine, 2019, Volume: 44, Issue:7

    Topics: Adult; Dihydroxyphenylalanine; Female; Humans; Insulinoma; Magnetic Resonance Imaging; Multimodal Im

2019
Solid pseudopapillary pancreatic tumor mimicking a neuroendocrine neoplasm on ¹⁸F-FDOPA PET/CT.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:7

    Topics: Adult; Carbidopa; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine Agents; Fluorine Radiois

2013
Topographic diagnosis: respective roles of morphological and functional imaging.
    Annales d'endocrinologie, 2013, Volume: 74, Issue:3

    Topics: 5-Hydroxytryptophan; Anatomy, Cross-Sectional; Diagnostic Imaging; Dihydroxyphenylalanine; Fluorodeo

2013
18F-FDOPA PET/CT imaging of insulinoma revisited.
    European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Dihydroxyphenylalanine; Female; Humans; Hyperinsulinism;

2015
Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia.
    Clinical nuclear medicine, 2015, Volume: 40, Issue:8

    Topics: Adult; Carbidopa; Dihydroxyphenylalanine; Female; Humans; Hyperinsulinism; Hypoglycemia; Insulinoma;

2015
Effect of Carbidopa on 18F-FDOPA Uptake in Insulinoma: From Cell Culture to Small-Animal PET Imaging.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017, Volume: 58, Issue:1

    Topics: Animals; Carbidopa; Cell Line, Tumor; Dihydroxyphenylalanine; Female; Image Enhancement; Insulinoma;

2017
Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-10, Volume: 26, Issue:32

    Topics: Carbidopa; Diagnostic Errors; Dihydroxyphenylalanine; Enzyme Inhibitors; Fluorine Radioisotopes; Hum

2008
Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:1

    Topics: Adolescent; Adult; Aged; Child; Dihydroxyphenylalanine; Female; Humans; Hyperinsulinism; Hypoglycemi

2010
Pancreatic and hepatobiliary cancers.
    Methods in molecular biology (Clifton, N.J.), 2011, Volume: 727

    Topics: Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Dihydroxyphenylalanine; Fluorodeoxyglucose F18;

2011
Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:4

    Topics: Adult; Central Nervous System Neoplasms; Cohort Studies; Contrast Media; Dihydroxyphenylalanine; Fem

2012
[Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
    Nederlands tijdschrift voor geneeskunde, 2006, Oct-28, Volume: 150, Issue:43

    Topics: Carcinoid Tumor; Dihydroxyphenylalanine; Gastrointestinal Neoplasms; Humans; Pancreatic Neoplasms; P

2006
Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:4

    Topics: Adult; Dihydroxyphenylalanine; Female; Humans; Hyperplasia; Insulin-Secreting Cells; Insulinoma; Mal

2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In

2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In

2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In

2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In

2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In

2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In

2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In

2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In

2007
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Biopsy; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Image Interpretation, Computer-Assisted; In

2007
Congenital hyperinsulinism: [18F]DOPA PET/CT scan of a focal lesion in the head of the pancreas.
    Archives of disease in childhood. Fetal and neonatal edition, 2008, Volume: 93, Issue:2

    Topics: Dihydroxyphenylalanine; Dopamine Agents; Humans; Hyperinsulinism; Image Interpretation, Computer-Ass

2008
Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: 5-Hydroxytryptophan; Adenoma, Islet Cell; Adult; Aged; Carbon Radioisotopes; Carcinoid Tumor; Dihydr

2008
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
    European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:8

    Topics: Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Gastrointestinal Neoplasms; Humans; Lung Ne

2008
[Biochemical tumor diagnosis in childhood].
    Schweizerische medizinische Wochenschrift, 1974, May-04, Volume: 104, Issue:18

    Topics: Adenoma, Islet Cell; Adrenal Gland Neoplasms; Carcinoma, Hepatocellular; Child; Cushing Syndrome; De

1974
[Distribution of DL-3 (3,4-dihydroxyphenyl)-alanine-2 C14 in the organism of mice with Cloudmann's S91 melanoma].
    Archives belges de dermatologie et de syphiligraphie, 1970, Volume: 26, Issue:2

    Topics: Adrenal Gland Neoplasms; Animals; Carbon Isotopes; Computers; Dihydroxyphenylalanine; Isocarboxazid;

1970